A novel Ebola virus disease treatment based on three monoclonal antibodies will advance in development through an agreement between the U.S. Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response and Regeneron Pharmaceuticals, Inc. of Tarrytown, N.Y. ASPR's Biomedical Advanced Research and Development Authority will provide up to a total of $38 million over the next 23 months to support development as well as manufacturing of the experimental monoclonal antibody therapeutic drug for use in studies. These monoclonal antibodies bind to a key Ebola viral protein and neutralize the virus, decreasing the amount of virus in the body that the patient's immune system has to fight.
http://ift.tt/1KqHeZC
No comments:
Post a Comment